Next Article in Journal
Stem Cells: Current Status and Therapeutic Implications
Next Article in Special Issue
‘There and Back Again’—Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension
Previous Article in Journal
Plant Organellar DNA Polymerases Evolved Multifunctionality through the Acquisition of Novel Amino Acid Insertions
Previous Article in Special Issue
Whole Exome Sequence Analysis Provides Novel Insights into the Genetic Framework of Childhood-Onset Pulmonary Arterial Hypertension
Review

At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension

1
Division of Pulmonary, Critical Care and Occupational Medicine, University of Utah, Salt Lake City, UT 84132, USA
2
Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Salt Lake City, UT 84107, USA
3
Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
4
Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN 46202, USA
5
Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
*
Author to whom correspondence should be addressed.
Genes 2020, 11(11), 1371; https://doi.org/10.3390/genes11111371
Received: 29 September 2020 / Revised: 10 November 2020 / Accepted: 17 November 2020 / Published: 20 November 2020
(This article belongs to the Special Issue Genetics and Genomics of Pulmonary Arterial Hypertension)
Group 1 pulmonary hypertension (pulmonary arterial hypertension; PAH) is a rare disease characterized by remodeling of the small pulmonary arteries leading to progressive elevation of pulmonary vascular resistance, ultimately leading to right ventricular failure and death. Deleterious mutations in the serine-threonine receptor bone morphogenetic protein receptor 2 (BMPR2; a central mediator of bone morphogenetic protein (BMP) signaling) and female sex are known risk factors for the development of PAH in humans. In this narrative review, we explore the complex interplay between the BMP and estrogen signaling pathways, and the potentially synergistic mechanisms by which these signaling cascades increase the risk of developing PAH. A comprehensive understanding of these tangled pathways may reveal therapeutic targets to prevent or slow the progression of PAH. View Full-Text
Keywords: bone morphogenetic protein receptor type 2; heritable; familial; estrogen; estradiol; penetrance; gender; PAH bone morphogenetic protein receptor type 2; heritable; familial; estrogen; estradiol; penetrance; gender; PAH
Show Figures

Figure 1

MDPI and ACS Style

Cirulis, M.M.; Dodson, M.W.; Brown, L.M.; Brown, S.M.; Lahm, T.; Elliott, G. At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension. Genes 2020, 11, 1371. https://doi.org/10.3390/genes11111371

AMA Style

Cirulis MM, Dodson MW, Brown LM, Brown SM, Lahm T, Elliott G. At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension. Genes. 2020; 11(11):1371. https://doi.org/10.3390/genes11111371

Chicago/Turabian Style

Cirulis, Meghan M., Mark W. Dodson, Lynn M. Brown, Samuel M. Brown, Tim Lahm, and Greg Elliott. 2020. "At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension" Genes 11, no. 11: 1371. https://doi.org/10.3390/genes11111371

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop